Literature DB >> 28740792

Team Work: Mastectomy, Reconstruction, and Radiation.

Orit Kaidar-Person1, Ellen L Jones1, Timothy M Zagar1.   

Abstract

Entities:  

Year:  2017        PMID: 28740792      PMCID: PMC5505853          DOI: 10.1097/GOX.0000000000001385

Source DB:  PubMed          Journal:  Plast Reconstr Surg Glob Open        ISSN: 2169-7574


× No keyword cloud information.
In November 2016, Umberto Veronesi, an Italian surgical oncologist and one of the founders of breast conserving surgery passed away. We have come a long way since the pivotal Milan and National Surgical Adjuvant Breast and Bowel Project trials in the 1980s that resulted in a paradigm shift in the management of breast cancer, leading to the acceptance of breast conserving surgery and whole breast irradiation. A recent publication surveying the National Cancer Database[1] demonstrates a new trend in the treatment of early-stage breast cancer patients, indicating an increase in the overall rates of mastectomies. Furthermore, the rate of bilateral mastectomies for unilateral disease is also increasing. The rates of bilateral mastectomies for unilateral disease increased from 5.4% of mastectomies in 1998 to 29.7% in 2011, with a concurrent increase in reconstructive procedures in this group from 36.9% to 57.2% during the same time period.[1] Cosmetic outcomes are probably an important factor driving these trends. However, these surgeries should be planned with the patient’s cancer diagnosis in mind as patients who undergo mastectomy often need postoperative radiation (PMRT). Moreover, in the past decade, there has been an increase in the number of patients with indications for PMRT,[2] especially after the publication from the Early Breast Cancer Trialists’ Collaborative Group in 2014, demonstrating that PMRT for patients with 1–3 lymph nodes who underwent mastectomy and axillary dissection reduced recurrence and breast cancer mortality.[3] Therefore, the potential need for PMRT should be taken into consideration in the management of patients who are planned for mastectomy. An axial view of tangential fields for left breast irradiation of a 37-year-old patient is shown in Figure 1. The patient was diagnosed with a 3.2-cm left breast, invasive ductal carcinoma, that was hormone receptor positive, and HER2 (human epidermal growth factor receptor 2) negative. Sentinel lymph node biopsy revealed 1 out of 1 positive lymph nodes, which was 0.5 cm in size with a focus of extracapsular extension. A genetic evaluation was performed and she tested negative for BRCA 1/2. She was treated with preoperative chemotherapy and underwent bilateral mastectomy and left axillary dissection, which demonstrated a complete pathological response in the left breast and in the lymph nodes (0 of 8 lymph nodes). The procedure was done with immediate bilateral reconstruction with prepectoralis saline implants. The patient was referred to our care for PMRT.
Fig. 1.

Axial view of tangential fields for left breast irradiation. A shared decision with the patient was to irradiate with shallow tangents fields with deep inspiration breath-hold technique to reduce the dose to the heart and the contralateral breast. Therefore, the medial portion of the left breast and the left internal mammary nodes are not included in the radiation field. In this case, due to her “new” reconstructed anatomy, we could not match a medial electron field to cover the medial portion of the breast and the internal mammary nodes. An intensity modulated radiation therapy arc-based technique was not used due to a high mean heart dose.

Axial view of tangential fields for left breast irradiation. A shared decision with the patient was to irradiate with shallow tangents fields with deep inspiration breath-hold technique to reduce the dose to the heart and the contralateral breast. Therefore, the medial portion of the left breast and the left internal mammary nodes are not included in the radiation field. In this case, due to her “new” reconstructed anatomy, we could not match a medial electron field to cover the medial portion of the breast and the internal mammary nodes. An intensity modulated radiation therapy arc-based technique was not used due to a high mean heart dose. There are many factors to discuss in this specific case, but we would like to highlight the main concern that led to this correspondence. In the case presented, the radiation treatment could not be done appropriately without compromising on normal tissue toxicity (i.e., lung dose, heart dose, dose to the contralateral reconstructed breast) or oncological outcomes (i.e., reducing the target volumes). Even though internal mammary irradiation might have added a survival benefit in this case as data from randomized trials suggest, we decided not to irradiate the internal mammary nodes to avoid high dose radiation to the heart and the contralateral breast.[4,5] Presurgical planning with a multidisciplinary perspective would have probably prevented this challenge and might have also resulted in better oncologic outcomes.
  5 in total

1.  Nationwide trends in mastectomy for early-stage breast cancer.

Authors:  Kristy L Kummerow; Liping Du; David F Penson; Yu Shyr; Mary A Hooks
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

2.  Regional Nodal Irradiation in Early-Stage Breast Cancer.

Authors:  Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

3.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

4.  Temporal Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With Changes in National Comprehensive Cancer Network Guidelines.

Authors:  Lane L Frasier; Sara Holden; Timothy Holden; Jessica R Schumacher; Glen Leverson; Bethany Anderson; Caprice C Greenberg; Heather B Neuman
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

5.  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

Authors:  P McGale; C Taylor; C Correa; D Cutter; F Duane; M Ewertz; R Gray; G Mannu; R Peto; T Whelan; Y Wang; Z Wang; S Darby
Journal:  Lancet       Date:  2014-03-19       Impact factor: 79.321

  5 in total
  3 in total

Review 1.  Pattern of local recurrence after mastectomy and reconstruction in breast cancer patients: a systematic review.

Authors:  Ji Hyeon Joo; Yongkan Ki; Wontaek Kim; Jiho Nam; Donghyun Kim; Jongmoo Park; Hyun Yul Kim; Youn Joo Jung; Ki Seok Choo; Kyung Jin Nam; Su Bong Nam
Journal:  Gland Surg       Date:  2021-06

2.  Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.

Authors:  Yuxi Zhang; Zhipeng Xu; Hui Chen; Xinchen Sun; Zhaoyue Zhang
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

3.  A Retrospective Dosimetric Analysis of the New ESTRO-ACROP Target Volume Delineation Guidelines for Postmastectomy Volumetric Modulated Arc Therapy After Implant-Based Immediate Breast Reconstruction.

Authors:  Kyung Hwan Chang; Jee Suk Chang; Kwangwoo Park; Seung Yeun Chung; Se Young Kim; Ryeong Hwang Park; Min Cheol Han; Jihun Kim; Hojin Kim; Ho Lee; Dong Wook Kim; Yong Bae Kim; Jin Sung Kim; Chae-Seon Hong
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.